Publications by authors named "J A Mariotti"
Background: The selection of the best donor for each specific patient is crucial for the success of allogeneic hematopoietic stem cell transplantation (HSCT). However, there is debate on the choice of the best donor when multiple suitable donors exist.
Methods: By using own data from two transplant centers, we have developed a calculator able to provide the patients' 2-year overall survival (OS) associated with each of the potential donor options during the selection process, in order to support the transplant physician during the choice.
Donor-specific anti-HLA antibodies (DSA) are an important cause of engraftment failure and may negatively impact survival outcomes of patients receiving allogeneic hematopoietic stem cell transplantation (HSCT) using an HLA-mismatched allograft. The incidence of DSA varies across studies, depending on individual factors, detection or identification methods and thresholds considered clinically relevant. Although DSA testing by multiplex bead arrays remains semiquantitative, it has been widely adopted as a standard test in most transplant centers.
View Article and Find Full Text PDFBackground Aims: Mounting evidence suggests that persistent cell expansion is the main driver for both efficacy and toxicity of chimeric antigen receptor (CAR) T-cell therapy. Hereby, we describe a case of delayed recurrent neurotoxicity associated with late CAR T-cells re-expansion.
Case Description: A 44-year-old man suffering from mantle cell lymphoma received brexu-cel.
Article Synopsis
- New immunotherapy treatments like bispecific T-cell engagers and checkpoint inhibitors are often used for patients with non-Hodgkin lymphoma who relapse after CAR T-cell therapy, but their long-term effects on stem cell transplants are unclear.
- A study compared outcomes of 27 patients who received allogeneic stem cell transplants (Allo-SCT) after immunotherapy to 28 patients who underwent Allo-SCT after standard treatment, finding similar survival rates and complications between the two groups.
- The study suggests that Allo-SCT is a safe and effective option for patients who respond to immunotherapy, potentially serving as a solid treatment strategy after CAR T-cell therapy failures.*